Ascendis Pharma (ASND) has released an update.
Ascendis Pharma A/S has announced promising results from their ApproaCH Trial of TransCon CNP, a treatment for children with achondroplasia, showing significant improvements in growth velocity compared to placebo. The trial’s positive outcomes suggest plans for regulatory submissions to the FDA and EMA in 2025. Additionally, TransCon CNP has demonstrated a favorable safety profile and is well-tolerated, with continuation in an open-label extension.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.
